SEC filings

Every report BrainStorm has filed with the U.S. Securities and Exchange Commission since January 2005. This page is rebuilt automatically from EDGAR four times a day.

BrainStorm Cell Therapeutics (OTCQB: BCLI) files under CIK 0001137883. Every document below opens on the SEC's EDGAR system, which holds the authoritative copy. This index covers filings from January 2005 onward; filings from 2001 to 2004 are on EDGAR.

View BrainStorm's complete filing history on SEC EDGAR

Section 16 filings

321 of the filings below are ownership reports filed by individuals rather than by the company.

Section 16(a) reports (Forms 3, 4 and 5) filed by BrainStorm's directors, officers and principal shareholders

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.